OECD Home › Health › By Country › Germany
English, PDF, 236kb
Progress has been made to reduce smoking rates and alcohol consumption in Germany, but obesity is on the rise as in most other EU countries. As in other EU countries, spending for prevention in Germany accounts only for around 3% of current health spending.
Specific country notes have been prepared using data from the database OECD Health Statistics 2014, June 2014 version. The notes are available in PDF format.
The global economic crisis has had a profound impact on people’s well-being, reaching far beyond the loss of jobs and income, and affecting citizens’ satisfaction with their lives and their trust in governments, according to a new OECD report.
To help inform the Conference on Managing Hospital Volumes, co-organised by the German Federal Ministry of Health and the OECD, and held on the 11th April 2013 in Berlin, the OECD Secretariat produced a paper to provide an international perspective on Germany’s situation and the current policy debate.
Across OECD countries some 83 million people suffer from diabetes. On current trends, that will rise to almost 100 million by 2030.
To assess the feasibility of using secondary data sets information to feed an output-based PPP approach for hospital services, we reviewed the main characteristics of diagnoses and procedures coding standards, DRG classification systems, and cost-finding methods used in selected OECD countries.
The mortality amenable to health care is defined as a possible indicator to measure the health care systems performance in preventing premature deaths that can be avoided by appropriate health care intervention. This paper assesses the feasibility of using this indicator in OECD countries.
For many of today’s new biomedical innovations, the distinctions between different forms of medical products such as drugs, diagnostics and devices no longer apply. Biomedicine also tends to realize its potential today through process innovation, even more than product innovation.
English, , 771kb
This paper (Health Working Paper No. 39) describes pharmaceutical pricing and reimbursement policies in Germany, considering them in the broader environment in which they operate, and assesses their impact on the achievement of a number of policy goals.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.